Showing results (31-40 of 37) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Medicine|December 6, 2021
Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case reportYu Yagi, Yusuke Kanemasa, An Ohigashi, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 6, 2023
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant]Yuka Morita, Yu Yagi, Yusuke Kanemasa, et al.European Journal of Haematology|May 27, 2025
Site- and Stage-Adapted Treatment Strategies for Gastrointestinal Diffuse Large B-Cell LymphomaYu Yagi, Yusuke Kanemasa, Yuki Sasaki, et al.Cancer Medicine|August 28, 2023
Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective studyYu Yagi, Yusuke Kanemasa, Yuki Sasaki, et al.Blood Advances|April 22, 2026
Drivers of Temporal Improvement in CAR T-Cell Therapy for Large B-Cell Lymphoma: A Japanese Nationwide Registry AnalysisYu Yagi, Yusuke Kanemasa, Toshiki Terao, et al.Journal of Clinical and Experimental Hematopathology : JCEH|June 26, 2024
Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapyYu Yagi, Yusuke Kanemasa, Yuki Sasaki, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|November 9, 2022
[Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience]Yu Yagi, Yusuke Kanemasa, Yuki Sasaki, et al.Pageof 4